Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.
about
Chemotherapy-and cancer-related nausea and vomitingManagement of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination ChemotherapyA Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and VomitingChemotherapy-induced nausea and vomiting: optimizing prevention and managementNeurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysisNeurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysisCheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Update and new trends in antiemetic therapy: the continuing need for novel therapies.Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomitingNeuropharmacology and management of chemotherapy-induced nausea and vomiting in patients with breast cancer.Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a reviewAprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting.Herbal medicines for the treatment of cancer chemotherapy-induced side effects.Pharmacokinetic evaluation of fosaprepitant dimeglumineAprepitant and fosaprepitant: a 10-year review of efficacy and safetyEfficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trialLiterature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems.Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitantSafety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016).Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy.Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy.Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.Aprepitant: drug-drug interactions in perspective.Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Use of high-dose cisplatin with aprepitant in an outpatient setting.Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
P2860
Q24644831-C9960B90-F630-468D-9921-C3E9B2DFF180Q26783177-6FC84CAE-B6B5-4A46-B182-0E687016CECAQ26784064-94724844-4428-44B2-8AFE-1EDC5D505057Q26852601-C21C87C1-FB99-461E-A1CD-4AF265BA3754Q26997344-63A380FA-66E3-4BA9-AFF1-0171835F9513Q28078513-0552012A-2F72-4628-8602-88F397B9FB4DQ33866119-3D3E8470-5DF4-4615-912F-F714A2C6AD43Q34121232-CDAB1D88-7E35-46A8-9B87-557A09932DB9Q34143667-93F1EF93-F532-4631-8FB3-B228CBCD02C7Q34239808-77391B1C-BC50-4A81-B7AB-C321C0E53315Q34403552-4C9E2227-8BD6-4D58-A704-9F441CC6FCE2Q34417851-CF68A374-307B-4292-9496-3F907D07B0EDQ34450534-F5792F42-2984-48C4-B412-725F04082072Q34987555-EDD1654C-1BA9-4FBC-BCA7-52BF9AA93E1DQ35066654-B13F480F-BD4B-4FC1-A697-99107872DE78Q35163168-6D248ED3-FB4E-4E99-AB9B-CE4A2E2A5F5EQ35345557-1C9E415F-7101-4916-B0B7-B2C99C77A651Q36070497-734EE493-06EA-4E90-ABBF-39F7F2465C4CQ36220364-BE7DEAE4-A2DB-4AA0-9048-74C71B42DC7DQ36222937-27940358-6D07-4F73-B442-288F7EB3F332Q36371595-880779E0-8BD6-433D-9911-7A51E8FD7D8CQ36416256-90976F1D-BF31-4D1D-A782-D28F7013A894Q36673972-549BAE7C-6895-43CB-813D-1152427B519DQ36702393-FDE95AD3-F169-49B9-A113-6553FB999617Q36800765-C1AC0303-FE63-4214-9320-BEC4FD7A315BQ36823546-C54F0ADF-B2B6-472D-A613-D6DE79DA4B7DQ36843470-B48AC169-3291-4CFC-8122-DB00B67296E3Q37111164-42723A2E-EB9C-4BF2-BBCC-B246EBEED95EQ37355479-289E2BAB-3540-40B7-8474-B9B856F74C52Q37475199-63E9E413-D3A3-4B45-9527-219C7D118607Q37480802-C65A0C2A-3ED5-4E6F-81DD-E6B1D5E7F3DCQ37636064-88703081-23C8-4E55-BBD0-28B7FF547E65Q37660556-0C4A8461-D719-4637-97DB-A8D31C6BC05EQ37661865-C86BEE92-F58B-433E-928C-3A472B9AE989Q37687368-BC015290-66A9-48B7-8C17-70E51B766207Q37736060-B5D7C407-1B2B-4191-9FA1-90934DD97F05Q37757799-E1A26905-2F50-4C72-AEE2-D57D4AB1C953Q37854702-36428077-5A9F-4D0C-8B87-2CF10095DBA2Q37924902-DEBA3DC2-86F3-4AA9-957B-23256C23B560Q37982438-3126C31D-5B46-4271-9EE1-43344F19B3E2
P2860
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Comparison of an aprepitant re ...... high-dose cisplatin treatment.
@en
type
label
Comparison of an aprepitant re ...... high-dose cisplatin treatment.
@en
prefLabel
Comparison of an aprepitant re ...... high-dose cisplatin treatment.
@en
P2093
P356
P1433
P1476
Comparison of an aprepitant re ...... high-dose cisplatin treatment.
@en
P2093
H J Schmoll
J von Pawel
S Poli-Bigelli
P304
P356
10.1093/ANNONC/MDL019
P577
2006-03-08T00:00:00Z